Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

NCT05255354 is registered in ClinicalTrials.gov with Adaptive Biotechnologies as lead sponsor.

NCT NCT05255354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05255354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
Lead sponsor
Adaptive Biotechnologies
Phase
Observational
Overall status
Recruiting
Start date
June 1, 2022
Completion date
December 31, 2026
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, follicular lymphoma, mantle cell lymphoma